000163548 001__ 163548
000163548 005__ 20230915092422.0
000163548 0247_ $$2doi$$a10.3390/diagnostics11122372
000163548 0247_ $$2pmid$$apmid:34943609
000163548 0247_ $$2pmc$$apmc:PMC8700661
000163548 0247_ $$2altmetric$$aaltmetric:120055403
000163548 037__ $$aDZNE-2022-00304
000163548 041__ $$aEnglish
000163548 082__ $$a610
000163548 1001_ $$00000-0002-8101-6535$$aLewczuk, Piotr$$b0
000163548 245__ $$aDistributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory.
000163548 260__ $$aBasel$$bMDPI$$c2021
000163548 3367_ $$2DRIVER$$aarticle
000163548 3367_ $$2DataCite$$aOutput Types/Journal article
000163548 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655197951_924
000163548 3367_ $$2BibTeX$$aARTICLE
000163548 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163548 3367_ $$00$$2EndNote$$aJournal Article
000163548 520__ $$aAmyloid β 42/40 concentration quotient has been empirically shown to improve accuracy of the neurochemical diagnostics of Alzheimer's Disease (AD) compared to the Aβ42 concentration alone, but this improvement in diagnostic performance has not been backed up by a theoretical argumentation so far. In this report we show that better accuracy of Aβ42/40 compared to Aβ1-42 is granted by fundamental laws of probability. In particular, it can be shown that the dispersion of a distribution of a quotient of two random variables (Aβ42/40) is smaller than the dispersion of the random variable in the numerator (Aβ42), provided that the two variables are proportional. Further, this concept predicts and explains presence of outlying observations, i.e., AD patients with falsely negatively high Aβ42/40 ratio, and non-AD subjects with extremely low, falsely positive, Aβ42/40 ratio.
000163548 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163548 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163548 650_7 $$2Other$$aAlzheimer’s disease
000163548 650_7 $$2Other$$aamyloid β
000163548 650_7 $$2Other$$adistribution of a random variable
000163548 650_7 $$2Other$$aprobability theory
000163548 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b1$$udzne
000163548 7001_ $$00000-0002-8096-3987$$aKornhuber, Johannes$$b2
000163548 7001_ $$00000-0001-7187-7115$$aVerhasselt, Anneleen$$b3
000163548 770__ $$aBiomarkers in Psychiatry
000163548 773__ $$0PERI:(DE-600)2662336-5$$a10.3390/diagnostics11122372$$gVol. 11, no. 12, p. 2372 -$$n12$$p2372$$tDiagnostics$$v11$$x2075-4418$$y2021
000163548 8564_ $$uhttps://pub.dzne.de/record/163548/files/DZNE-2022-00304.pdf$$yOpenAccess
000163548 8564_ $$uhttps://pub.dzne.de/record/163548/files/DZNE-2022-00304.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163548 909CO $$ooai:pub.dzne.de:163548$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000163548 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000163548 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163548 9141_ $$y2021
000163548 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000163548 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000163548 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000163548 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000163548 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163548 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000163548 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIAGNOSTICS : 2021$$d2022-11-10
000163548 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-10
000163548 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-10
000163548 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-08-18T10:46:39Z
000163548 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-08-18T10:46:39Z
000163548 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-08-18T10:46:39Z
000163548 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-10
000163548 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-10
000163548 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-10
000163548 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-10
000163548 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-10
000163548 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-10
000163548 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lAlzheimer Biomarker and Clinical Study Group$$x0
000163548 980__ $$ajournal
000163548 980__ $$aVDB
000163548 980__ $$aUNRESTRICTED
000163548 980__ $$aI:(DE-2719)1410006
000163548 9801_ $$aFullTexts